NEW YORK, Feb 15 – Variagenics said Thursday its fourth-quarter revenues jumped to $1.2 million, compared with $100,000 in the previous year while revenues for the year rose to $2.3 million from $400,000.

"The year 2000 was pivotal for Variagenics as we commercialized our proprietary technologies for identifying drug-specific genetic markers," Taylor Crouch, CEO of Variagenics, said in a statement. "We are pursuing a vision to place Variagenics' pharmacogenomics at the heart of a new generation of individualized drugs and companion diagnostics.”